Biocartis Group NV announced the launch of its Idylla SARS-CoV-2/Flu/RSV Panel (CE-IVD). Building upon the success of its Idylla SARS-CoV-2 Test (CE-IVD), the new Panel is launching as a CE-IVD and detects, in one single cartridge, SARS-CoV-2, Flu A/B and RSV1 nucleic acids, with results in approx. 90 minutes. The Idylla SARS-CoV-2/Flu/RSV Panel is a fully automated rRT-PCR2 test intended for the qualitative detection of SARS-CoV-2, Flu A/B and RSV nucleic acids in nasopharyngeal swab specimens from individuals suspected of respiratory infections by their healthcare provider. The nasopharyngeal swab specimens are collected in a viral transport medium3 and can be pipetted directly into the cartridge. The Idylla SARS-CoV-2/Flu/RSV Panel includes fully automated nucleic acid testing with the extraction, amplification and detection in a single-use cartridge, with less than 1 minute hands-on time. The Panel showed excellent performance in the clinical performance study with 98% overall concordance compared with other currently used methods.